Nervous System News and Research

Latest Nervous System News and Research

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence.

24 May 2010

Study: Th1 cells play a vital role in pathogenesis of immune-mediated diseases

Current research suggests that T helper-type 1 (Th1) cells, previously thought to mediate autoimmunity, may actual inhibit the development of experimental immune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS), by suppressing Th17 cells.

24 May 2010

Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol

Bayer HealthCare Pharmaceuticals, Inc. today announced presentation of data in a poster titled "Results from a multicenter, open-label Phase 3 study to determine the safety and efficacy of gadobutrol, a macrocyclic 1.0 molar GBCA in patients referred for contrast-enhanced MRI of the central nervous system (CNS)" at the 48th Annual Meeting of the American Society of Neuroradiology (ASNR) in Boston, MA.

24 May 2010

Researchers study correlation between type 2 diabetes and increased risk of cancer

Cancer and diabetes - are risk factors the same for these two diseases? Or does diabetes cause processes in the body which promote the onset or growth of cancer? It is still unclear why diabetics have a higher rate of cancer than people who are not affected by this metabolic disorder.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

NeuroTherapeutics Pharma closes $43 million Series B financing round

NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co-led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round.

20 May 2010

AANS/CNS issue statement on Congress hearing of impact of concussions on high school athletes

On Thursday, May 20, 2010, the U.S. House of Representatives Committee on Education and Labor held a hearing to learn more about the impact of concussions on high school athletes and how the injury can impact academic achievement. A concussion is an injury to the brain that results in loss of normal brain function and is usually temporary.

20 May 2010

Basque researchers find new Alzheimer's-related mechanism

Researchers from the University of the Basque Country have found a new Alzheimer's-related mechanism that could give rise to the development of new therapies against this disease. The study was recently published in the Cell Calcium journal, and the authors have already applied for a European patent to protect the commercial exploitation of this new discovery.

20 May 2010

Grifols reaches agreement with Pharmalink to acquire PPS drug development project

Today, Grifols SA announced that it has reached an agreement with the Swedish company Pharmalink AB to acquire various forms of intellectual property associated with the treatment of post-polio syndrome. The acquisition is expected to be finalized in the next few weeks and will include documentation, know-how, and Swedish regulatory approvals under the trade name Xepol.

20 May 2010

US subsidiary of Novartis disputes claims of discrimination

Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG, strongly disputes the claims of past discrimination in the sales force during the period of 2002 to 2007.

20 May 2010

Role of neurotransmitter acetylcholine may suggest new treatment for Parkinson's disease: Researchers

Chicago and Montreal researchers studying the lowly lamprey eel have identified an overlooked nervous system pathway running parallel to known brainstem locomotor command circuitry in vertebrates such as birds, fishes and mammals.

20 May 2010

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

Improved treatment of severe epilepsy could reduce the overall cost of the condition, according to research presented at the annual meeting of the International Society of Pharmacoeconomic Outcomes Research at the Hilton Atlanta in Atlanta, Georgia.

20 May 2010

New study shows CDPK1 controls toxoplasma's ability to secrete microneme proteins

Researchers at Washington University School of Medicine in St. Louis have identified a parasite protein that has all the makings of a microbial glass jaw: it's essential, it's vulnerable and humans have nothing like it, meaning scientists can take pharmacological swings at it with minimal fear of collateral damage.

20 May 2010

Initial results of MUSIC Trial using PD2i in chronic heart failure patients released

David H. Fater, CEO of Vicor Technologies, Inc., today announced the initial results of a study designed to analyze data from the Merte Subita en Insufficiencia Cardiaca Trial using its PD2i- algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i- nonlinear algorithm and software.

20 May 2010

FDA grants 510(k) market clearance for EraGen's MultiCode-RTx HSV 1&2 Kit

EraGen Biosciences Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for EraGen's MultiCode®-RTx HSV 1&2 Kit.

20 May 2010

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).

19 May 2010

Children with new/recent onset epilepsy have slowed expansion of white matter volume

A newly published study reported that children with new/recent onset epilepsy have significantly slowed expansion of white matter volume compared to healthy children over a two year interval. The reduced white matter volume may affect brain connectivity and influence cognition. Results of this study conducted by researchers from the University of Wisconsin School of Medicine and Public Health are now available online and will appear in the July issue of Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

19 May 2010

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

Evotec AG today announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million.

19 May 2010

i3 completes acquisition of ChinaGate

i3, a global life sciences services company and subsidiary of Ingenix, has acquired ChinaGate, a contract research organization that provides product-development regulatory services for pharmaceutical, medical device and biotechnology companies looking to enter and access the Chinese market.

19 May 2010

Nervous System News and Research

Latest Nervous System News and Research

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

Study: Th1 cells play a vital role in pathogenesis of immune-mediated diseases

Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol

Researchers study correlation between type 2 diabetes and increased risk of cancer

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Genentech to present new data for targeted cancer medicines at 46th ASCO

NeuroTherapeutics Pharma closes $43 million Series B financing round

AANS/CNS issue statement on Congress hearing of impact of concussions on high school athletes

Basque researchers find new Alzheimer's-related mechanism

Grifols reaches agreement with Pharmalink to acquire PPS drug development project

US subsidiary of Novartis disputes claims of discrimination

Role of neurotransmitter acetylcholine may suggest new treatment for Parkinson's disease: Researchers

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

New study shows CDPK1 controls toxoplasma's ability to secrete microneme proteins

Initial results of MUSIC Trial using PD2i in chronic heart failure patients released

FDA grants 510(k) market clearance for EraGen's MultiCode-RTx HSV 1&2 Kit

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Children with new/recent onset epilepsy have slowed expansion of white matter volume

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

i3 completes acquisition of ChinaGate

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Nervous System News and Research

Latest Nervous System News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in